摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

6-溴-1-甲基吲唑-3-甲酸甲酯 | 946427-77-6

中文名称
6-溴-1-甲基吲唑-3-甲酸甲酯
中文别名
——
英文名称
methyl 6-bromo-1-methyl-1H-indazole-3-carboxylate
英文别名
methyl 6-bromo-1-methyl-indazole-3-carboxylate;methyl 6-bromo-1-methylindazole-3-carboxylate
6-溴-1-甲基吲唑-3-甲酸甲酯化学式
CAS
946427-77-6
化学式
C10H9BrN2O2
mdl
——
分子量
269.098
InChiKey
SJICLOHNXORMBV-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 沸点:
    366.7±22.0 °C(Predicted)
  • 密度:
    1.61±0.1 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    2.4
  • 重原子数:
    15
  • 可旋转键数:
    2
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.2
  • 拓扑面积:
    44.1
  • 氢给体数:
    0
  • 氢受体数:
    3

安全信息

  • 海关编码:
    2933990090

SDS

SDS:4bdc3f74b2613ceb3a9ea3fe94e05633
查看

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量
  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    描述:
    6-溴-1-甲基吲唑-3-甲酸甲酯tris-(dibenzylideneacetone)dipalladium(0) 、 palladium diacetate 、 三(邻甲基苯基)磷 三乙胺 作用下, 以 乙醚N,N-二甲基甲酰胺 为溶剂, 反应 16.0h, 生成 Methyl 6-[2-[2-chloro-4-[[5-cyclopropyl-3-(2,6-dichlorophenyl)-1,2-oxazol-4-yl]methoxy]phenyl]cyclopropyl]-1-methylindazole-3-carboxylate
    参考文献:
    名称:
    [EN] NOVEL FXR (NR1H4 ) BINDING AND ACTIVITY MODULATING COMPOUNDS
    [FR] NOUVEAUX COMPOSÉS SE LIANT AU FXR (NR1 H4) ET MODULANT SON ACTIVITÉ
    摘要:
    本发明涉及结合NR1 H4受体(FXR)并作为NR1 H4受体(FXR)激动剂的化合物。该发明还涉及利用这些化合物制备药物用于通过这些化合物结合所述核受体治疗疾病和/或症状,并涉及这些化合物的合成过程。
    公开号:
    WO2011020615A1
  • 作为产物:
    参考文献:
    名称:
    WO2007/92751
    摘要:
    公开号:
点击查看最新优质反应信息

文献信息

  • [EN] COMPOUNDS AND METHODS FOR MODULATING FXR<br/>[FR] COMPOSÉS ET PROCÉDÉS POUR MODULER LE FXR
    申请人:LILLY CO ELI
    公开号:WO2009012125A1
    公开(公告)日:2009-01-22
    Compounds of formula (I): formula (I) wherein variables are as defined herein and their pharmaceutical compositions and methods of use are disclosed as useful for treating dyslipidemia and diseases related to dyslipidemia.
    公式(I)的化合物:其中变量如本文所述定义,其药物组合物及其用途被披露为用于治疗血脂异常以及与血脂异常相关的疾病。
  • [EN] PESTICIDAL COMPOUNDS<br/>[FR] COMPOSÉS PESTICIDES
    申请人:BASF SE
    公开号:WO2018177781A1
    公开(公告)日:2018-10-04
    The present invention relates to the compounds of formula (I), and the N-oxides, stereoisomers, tautomers and agriculturally or veterinarily acceptable salts thereof wherein the variables are defined according to the description, (I). The compounds of formula (I), as well as the N-oxides, stereoisomers, tautomers and agriculturally or veterinarily acceptable salts thereof, are useful for combating or controlling invertebrate pests, in particular arthropod pests and nematodes. The invention also relates to a method for controlling invertebrate pests by using these compounds and to plant propagation material and to an agricultural and a veterinary composition comprising said compounds.
    本发明涉及式(I)的化合物,以及其N-氧化物、立体异构体、互变异构体和农业或兽医可接受的盐,其中变量根据描述(I)中定义。式(I)的化合物以及其N-氧化物、立体异构体、互变异构体和农业或兽医可接受的盐对于对抗或控制无脊椎动物害虫,特别是节肢动物害虫和线虫是有用的。该发明还涉及一种通过使用这些化合物来控制无脊椎动物害虫的方法,以及包括所述化合物的植物繁殖材料和农业和兽医组合物。
  • Novel FXR (NR1H4) binding and activity modulating compounds
    申请人:Phenex Pharmaceuticals AG
    公开号:EP2545964A1
    公开(公告)日:2013-01-16
    The present invention relates to compounds which bind to the NR1H4 receptor (FXR) and act as agonists of the NR1H4 receptor (FXR). The invention further relates to the use of the compounds for the preparation of a medicament for the treatment of diseases and/or conditions through binding of said nuclear receptor by said compounds and to a process for the synthesis of said compounds. wherein R is selected from the group consisting of COOR6, CONR7R8, tetrazolyl, SO2NR7R8, C1-6 alkyl, SO2-C1-6 alkyl and H, with R6 independently selected from the group consisting of H or C1-6 alkyl, and R7 and R8 independently from each other selected from the group consisting of H, C1-6 alkyl, halo-C1-6 alkyl, C1-6 alkylene-R9, SO2-C1-6 alkyl, wherein R9 is selected from the group consisting of COOH, OH and SO3H; A is selected from the group consisting of phenyl, pyridyl, pyrimidyl, pyrazolyl, indolyl, thienyl, benzothienyl, indazolyl, benzisoxazolyl, benzofuranyl, benzotriazolyl, furanyl, benzothiazolyl, thiazolyl, oxadiazolyl, each optionally substituted with one or two groups independently selected from the group consisting of OH, O-C1-6 alkyl, O-halo-C1-6 alkyl, C1-6 alkyl, halo-C1-6 alkyl, C3-6 cycloalkyl and halogen; Q is selected from the group consisting of phenyl, pyridyl, thiazolyl, thiophenyl, pyrimidyl, each optionally substituted with one or two groups independently selected from the group consisting of C1-6 alkyl, halo-C1-6 alkyl, halogen and CF3; Y is selected from N or CH; Z is selected from wherein X= CH, N, NO.
    本发明涉及与NR1H4受体(FXR)结合并作为NR1H4受体(FXR)激动剂的化合物。该发明还涉及利用这些化合物制备用于治疗疾病和/或病况的药物,通过这些化合物结合所述核受体来实现,并涉及一种合成这些化合物的方法。其中R从COOR6,CONR7R8,四唑基,SO2NR7R8,C1-6烷基,SO2-C1-6烷基和H组成的群体中选择,R6独立地从H或C1-6烷基组成的群体中选择,R7和R8相互独立地从H,C1-6烷基,卤代C1-6烷基,C1-6烷基烯基-R9,SO2-C1-6烷基中选择,其中R9从COOH,OH和SO3H组成的群体中选择;A从苯基,吡啶基,嘧啶基,吡唑基,吲哚基,噻吩基,苯并噻吩基,吲哚啉基,苯并异噁唑基,苯并呋喃基,苯并三唑基,呋喃基,苯并噻唑基,噻唑基,氧代二唑基中选择,每种基可选择地被一个或两个基独立地从OH,O-C1-6烷基,O-卤代C1-6烷基,C1-6烷基,卤代C1-6烷基,C3-6环烷基和卤素取代;Q从苯基,吡啶基,噻唑基,噻吩基,嘧啶基中选择,每种基可选择地被一个或两个基独立地从C1-6烷基,卤代C1-6烷基,卤素和CF3中选择;Y从N或CH中选择;Z从中选择其中X= CH,N,NO。
  • NOVEL FXR (NR1H4) BINDING AND ACTIVITY MODULATING COMPOUNDS
    申请人:Kinzel Olaf
    公开号:US20140221659A1
    公开(公告)日:2014-08-07
    The present invention relates to compounds which bind to the NR1H4 receptor (FXR) and act as agonists of FXR. The invention further relates to the use of the compounds for the preparation of a medicament for the treatment of diseases and/or conditions through binding of said nuclear receptor by said compounds and to a process for the synthesis of said compounds.
    本发明涉及结合NR1H4受体(FXR)并作为FXR激动剂的化合物。该发明还涉及利用这些化合物制备药物以治疗疾病和/或病况,通过这些化合物结合所述核受体,并涉及这些化合物的合成过程。
  • [EN] 4-HETEROARYLCARBONYL-N-(PHENYL OR HETEROARYL) PIPERIDINE-1-CARBOXAMIDES AS INHIBITORS OF TANKYRASES<br/>[FR] 4-HÉTÉROARYLCARBONYL-N-(PHÉNYLE OU HÉTÉROARYL) PIPÉRIDINE-1-CARBOXAMIDES SERVANT D'INHIBITEURS DE TANKYRASES
    申请人:MERCK PATENT GMBH
    公开号:WO2020114892A1
    公开(公告)日:2020-06-11
    Compounds of the formula (I) in which R1, R2 and R3 have the meanings indicated in Claim 1, are inhibitors of Tankyrase, and can be employed, inter alia, for the treatment of diseases such as cancer, multiple sclerosis, cardiovascular diseases, central nervous system injury and different forms of inflammation.
    式(I)中R1、R2和R3具有权利要求1中所指示的含义的化合物是坦克酶的抑制剂,可以用于治疗癌症、多发性硬化症、心血管疾病、中枢神经系统损伤和不同形式的炎症等疾病。
查看更多